A traditional Chinese medicine composition for treating postoperative discomfort of lung cancer and / or reducing lung nodules and application thereof

Abstract

The present application relates to the technical field of traditional Chinese medicine, in particular to a traditional Chinese medicine composition for treating postoperative discomfort of lung cancer and / or reducing lung nodules and application thereof. The traditional Chinese medicine composition is prepared according to the theory of traditional Chinese medicine, and the prescription aims to regulate the lung, supplement qi, resolve phlegm and remove stasis, remove pathogenic factors in the lung, and restore the descending function of the lung. The traditional Chinese medicine composition can be used in the postoperative stage of lung cancer, especially the postoperative stage of non-small cell lung cancer, to improve postoperative symptoms such as cough, expectoration, chest pain and fatigue. The traditional Chinese medicine composition has mild drug properties and high safety. The traditional Chinese medicine composition comprises 15 kinds of traditional Chinese medicines, the legal standard sources of the medicinal properties are clear, no medicinal materials with toxicity or modern toxicological evidence of toxicity are contained, there is no compatibility taboo of eighteen incompatibilities and nineteen incompatibilities, and the dosages of the medicinal properties are within the standard range.

Description

TECHNICAL FIELD

[0001] The present application relates to the technical field of traditional Chinese medicine, in particular to a traditional Chinese medicine composition for treating postoperative discomfort of lung cancer and / or reducing lung nodules and application thereof. BACKGROUND

[0002] Non-small cell lung cancer accounts for about 85% of lung cancer, and surgery is one of the main means for treating non-small cell lung cancer. The basic principle of surgical treatment is to remove cancerous tissue while preserving as much healthy lung tissue as possible to benefit the survival of patients. At present, thoracoscopic surgery is widely used in clinical practice due to its smaller trauma and higher safety than traditional open chest surgery, and the surgical procedures include lobectomy, segmentectomy, and wedge resection, etc. However, due to factors such as tissue resection, lymph node dissection, and anesthesia, postoperative clinical problems still exist after lung cancer surgery, and most patients experience postoperative discomfort symptoms, mainly including cough, sputum, chest tightness, chest pain, fatigue, etc. Research data shows that the incidence of postoperative cough after lung cancer surgery is 37.2% at discharge, 66.1% at 30 days after discharge, and 66.0% at 90 days after discharge. The incidence of pain is 55.7% at discharge, 23.7% at 30 days after discharge, and 12.0% at 90 days after discharge. The incidence of fatigue is 7.1% at discharge, 10.2% at 30 days after discharge, and 22.0% at 90 days after discharge. Cough is a common postoperative discomfort symptom in patients, with a high incidence of 30% to 50%. Due to intraoperative damage to lung tissue and glands, bronchial traction, and other factors, the airway is in a state of high reaction, and postoperative cough reflex increases. Short-term cough after lung cancer surgery can promote lung recruitment and remove secretions, but the cough symptoms of some patients can last for several months to several years, and persistent cough exacerbates the psychological burden of patients. Chronic pain after lung cancer surgery is mainly related to intercostal nerve damage, nerve sensitivity, and chronic inflammation, etc. The incidence of chronic pain after open chest surgery is 65%. Postoperative pain in lung cancer patients seriously affects their mood, and pain can limit the patient's cough and expectoration, which may cause complications such as pulmonary infection. In addition, after lobectomy or segmentectomy, the effective ventilation area of the lung decreases, causing ventilation and gas exchange disorders, and patients may experience chest tightness and dyspnea. Postoperative fatigue syndrome is also a common symptom after lung cancer surgery.

[0003] Postoperative discomfort symptoms can last for 3 months or more, even up to 5 years, seriously affecting the quality of life of patients, and the occurrence and persistence of postoperative symptoms are associated with a worse prognosis. Scientific evaluation and effective management of postoperative symptoms are conducive to the postoperative rehabilitation of patients. In terms of treatment, Western medicine adopts symptomatic treatment, and central or peripheral antitussive drugs are used to relieve cough, sputum dissolving agents are used to promote sputum excretion, non-steroidal anti-inflammatory drugs are used to relieve pain, however, Western medicine treatment has little effect on cough, sputum and pain, and has many adverse reactions, and lacks effective medical treatment for symptoms such as fatigue and chest tightness. In addition, 6% of patients with early lung cancer who undergo radical resection are accompanied by ground glass nodules that cannot be resected at the same time. In the development process from lung nodules to lung cancer, the doubling time of malignant solid nodules is mostly 30-400 days, while some solid nodules and ground glass density nodules often grow inertly, and their volume doubling time is significantly longer than 400 days. At present, there is a lack of medical treatment for lung nodules, and only follow-up observation is adopted. At present, there is a lack of effective treatment for postoperative symptom management and lung nodules in early lung cancer. SUMMARY

[0004] In order to solve the above problems, the present application provides a traditional Chinese medicine composition for treating postoperative discomfort symptoms of lung cancer and / or reducing lung nodules and its application. The traditional Chinese medicine composition provided by the present application has the effects of tonifying qi and nourishing yin, resolving phlegm and removing stasis, and can effectively relieve postoperative cough, fatigue and other discomfort symptoms of lung cancer and reduce lung nodules.

[0005] In order to achieve the above-mentioned purpose, the present application provides the following technical solutions:

[0006] The present application provides a traditional Chinese medicine composition, which comprises the following components in parts by mass: floating sea stone 15-60 parts, xuanfuhua 5-10 parts, radix astragali 30-50 parts, schisandra 5-10 parts, angelica 10-20 parts, white peony root 10-20 parts, caulis et ramus morindae 10-20 parts, prunella vulgaris 10-20 parts, pre-know son 9-15 parts, motherwort 20-30 parts, taraxacum 10-20 parts, oldenlandia 20-30 parts, fagopyrum 10-20 parts, platycodon 10-20 parts and licorice 5-10 parts.

[0007] Preferably, it comprises the following components in parts by mass: floating sea stone 15 parts, xuanfuhua 9 parts, radix astragali 30 parts, schisandra 6 parts, angelica 12 parts, white peony root 15 parts, caulis et ramus morindae 15 parts, prunella vulgaris 10 parts, pre-know son 9 parts, motherwort 30 parts, taraxacum 10 parts, oldenlandia 30 parts, fagopyrum 15 parts, platycodon 10 parts and licorice 10 parts.

[0008] The present application provides the application of the traditional Chinese medicine composition in the preparation of a drug for treating postoperative discomfort symptoms of lung cancer and / or reducing lung nodules.

[0009] Preferably, the postoperative discomfort of lung cancer includes one or more of cough, expectoration, chest pain, fatigue, sweating symptoms and constipation.

[0010] The present application provides a medicine for treating postoperative discomfort of lung cancer and / or reducing lung nodules, and the raw material for preparing the medicine comprises the traditional Chinese medicine composition described in the above technical solution.

[0011] Preferably, the medicine further comprises a medically acceptable auxiliary.

[0012] Preferably, the dosage form of the medicine comprises decoction, tablet, capsule, granule, oral liquid or dripping pill.

[0013] The present application provides a preparation method of the medicine described in the above technical solution, comprising the following steps:

[0014] The traditional Chinese medicine composition described in the above technical solution is decocted to obtain medicinal liquid.

[0015] Preferably, when the dosage form of the medicine is granule, the preparation method further comprises the following steps:

[0016] The medicinal liquid is concentrated and mixed with dextrin to obtain a mixture;

[0017] The mixture is mixed with an ethanol solution to obtain soft material;

[0018] The soft material is sieved and dried to obtain the granule.

[0019] The present application provides the application of the medicine described in the above technical solution or the medicine prepared by the preparation method described in the above technical solution in preparing a product for treating postoperative discomfort of lung cancer and / or reducing lung nodules.

[0020] Beneficial effects:

[0021] This invention provides a traditional Chinese medicine composition comprising the following components in parts by weight: 15-60 parts of pumice, 5-10 parts of Inula japonica, 30-50 parts of Astragalus membranaceus, 5-10 parts of Schisandra chinensis, 10-20 parts of Angelica sinensis, 10-20 parts of Paeonia lactiflora, 10-20 parts of Spatholobus suberectus, 10-20 parts of Prunella vulgaris, 9-15 parts of Citrus aurantium, 20-30 parts of Leonurus japonicus, 10-20 parts of Taraxacum mongolicum, 20-30 parts of Hedyotis diffusa, 10-20 parts of Fagopyrum diffusa, 10-20 parts of Platycodon grandiflorus, and 5-10 parts of Glycyrrhiza uralensis. The traditional Chinese medicine composition provided by this invention has the effects of invigorating qi and nourishing yin, resolving phlegm and dissipating nodules, and detoxifying and removing blood stasis. It can effectively alleviate postoperative cough, fatigue, and other discomfort symptoms after lung cancer surgery and shrink pulmonary nodules. The traditional Chinese medicine composition provided by this invention uses pumice and inula as the principal herbs. Pumice is salty and cold in nature; its saltiness can soften hardness and dissipate nodules, while its coldness can clear heat and resolve phlegm. Inula is bitter, pungent, and salty, and slightly warm; its function is to lower qi and resolve phlegm. While all other stones descend, pumice alone ascends; while all other flowers ascend, inula alone descends. The combination of these two herbs, with their ascending and descending functions mutually reinforcing each other, restores the lung's function of dispersing and descending qi. Astragalus and Schisandra chinensis tonify qi and nourish yin, promoting lung recovery; Angelica sinensis, Paeonia lactiflora, Spatholobus suberectus, and Leonurus japonicus nourish blood, invigorate blood circulation, remove blood stasis, and relieve pain; Prunella vulgaris, Taraxacum mongolicum, and Anemarrhena asphodeloides clear heat, regulate qi, and dissipate nodules; Hedyotis diffusa and Fagopyrum dibotrys clear heat and detoxify. These are the assistant herbs. Platycodon grandiflorus is the adjuvant herb, resolving phlegm and draining pus, and carrying the medicine upwards; Glycyrrhiza uralensis is the guiding herb, harmonizing the other herbs. Overall, the formula works to tonify qi and nourish yin, resolve phlegm and dissipate nodules, and detoxify and remove blood stasis. Attached Figure Description

[0022] To more clearly illustrate the technical solutions in the embodiments of the present invention or the prior art, the accompanying drawings used in the embodiments will be briefly described below.

[0023] Figure 1 Changes in symptoms before and after lung cancer surgery;

[0024] Figure 2 Changes in target pulmonary nodules before and after lung cancer surgery;

[0025] Figure 3 The images show the patient's CT scan results before and after treatment; where A represents the CT scan result before treatment and B represents the CT scan result after treatment.

[0026] Figure 4 The target intersection of the effects of traditional Chinese medicine composition on lung cancer after surgery;

[0027] Figure 5 For the treatment of lung cancer with a traditional Chinese medicine composition, a PPI network was established after surgery.

[0028] Figure 6 A target map of the effective components of a traditional Chinese medicine composition for treating lung cancer after surgery;

[0029] Figures 7-10 The results of functional and pathway enrichment analysis of relevant targets for traditional Chinese medicine composition in the treatment of lung cancer after surgery. DETAILED DESCRIPTION

[0030] The present application provides a traditional Chinese medicine composition, which comprises the following components in parts by mass: floating sea stone 15-60 parts, xuanfuhua 5-10 parts, huangqi 30-50 parts, wuweizi 5-10 parts, danggui 10-20 parts, baishao 10-20 parts, jixueteng 10-20 parts, xiaakucao 10-20 parts, yimucao 20-30 parts, pugongying 10-20 parts, baihuasheshecao 20-30 parts, jinqiao 10-20 parts, jiegeng 10-20 parts and gancao 5-10 parts.

[0031] The present application does not have special requirements for the sources of the components of the traditional Chinese medicine composition, and commercially available products known to those skilled in the art can be used.

[0032] The traditional Chinese medicine composition of the present application comprises floating sea stone 15-60 parts, preferably 15-30 parts, and more preferably 15 parts, in parts by mass.

[0033] The traditional Chinese medicine composition of the present application comprises xuanfuhua 5-10 parts, preferably 7-9 parts, and more preferably 9 parts, in parts by mass based on the mass of the floating sea stone.

[0034] The traditional Chinese medicine composition of the present application comprises huangqi 30-50 parts, preferably 30-40 parts, and more preferably 30 parts, in parts by mass based on the mass of the floating sea stone.

[0035] The traditional Chinese medicine composition of the present application comprises wuweizi 5-10 parts, preferably 5-8 parts, and more preferably 6 parts, in parts by mass based on the mass of the floating sea stone.

[0036] The traditional Chinese medicine composition of the present application comprises danggui 10-20 parts, preferably 11-15 parts, and more preferably 12 parts, in parts by mass based on the mass of the floating sea stone.

[0037] The traditional Chinese medicine composition of the present application comprises baishao 10-20 parts, preferably 12-18 parts, and more preferably 15 parts, in parts by mass based on the mass of the floating sea stone.

[0038] The traditional Chinese medicine composition of the present application comprises jixueteng 10-20 parts, preferably 12-18 parts, and more preferably 15 parts, in parts by mass based on the mass of the floating sea stone.

[0039] The traditional Chinese medicine composition of the present application comprises xiaakucao 10-20 parts, preferably 10-15 parts, and more preferably 10 parts, in parts by mass based on the mass of the floating sea stone.

[0040] The traditional Chinese medicine composition of the present application comprises yimucao 20-30 parts, preferably 20-25 parts, and more preferably 20 parts, in parts by mass based on the mass of the floating sea stone.

[0041] The traditional Chinese medicine composition comprises Motherwort 20-30 parts, preferably 25-30 parts, and more preferably 30 parts, based on the mass parts of the floating sea stone.

[0042] The traditional Chinese medicine composition comprises Dandelion 10-20 parts, preferably 10-15 parts, and more preferably 10 parts, based on the mass parts of the floating sea stone.

[0043] The traditional Chinese medicine composition comprises Whiteflower Herba 20-30 parts, preferably 25-30 parts, and more preferably 30 parts, based on the mass parts of the floating sea stone.

[0044] The traditional Chinese medicine composition comprises Fagopyrum Cymosum 10-20 parts, preferably 12-17 parts, and more preferably 15 parts, based on the mass parts of the floating sea stone.

[0045] The traditional Chinese medicine composition comprises Platycodon 10-20 parts, preferably 10-15 parts, and more preferably 10 parts, based on the mass parts of the floating sea stone.

[0046] The traditional Chinese medicine composition comprises Licorice 5-10 parts, preferably 8-10 parts, and more preferably 10 parts, based on the mass parts of the floating sea stone.

[0047] The traditional Chinese medicine composition is prepared according to the theory of traditional Chinese medicine, and is used for regulating the lung and tonifying qi, resolving phlegm and removing stasis, removing pathogenic factors in the lung, and restoring the descending function of the lung. The traditional Chinese medicine composition can be used for the postoperative stage of lung cancer, especially the postoperative stage of non-small cell lung cancer, and can improve the symptoms such as postoperative cough, expectoration, chest pain and fatigue.

[0048] The traditional Chinese medicine composition has mild medicinal properties and high safety. The 15 traditional Chinese medicines in the composition have clear sources of legal standards, do not contain any medicine materials with toxicity or modern toxicological evidence of toxicity, have no compatibility taboos of eighteen incompatibilities and nineteen incompatibilities, and the dosages of the medicine materials are within the standard range.

[0049] The application also provides the use of the traditional Chinese medicine composition in the preparation of a medicine for treating postoperative discomfort of lung cancer and / or reducing lung nodules. In the application, the postoperative discomfort of lung cancer preferably includes one or more of cough, expectoration, chest pain, fatigue, sweating and constipation; the sweating preferably includes spontaneous sweating and / or night sweating; and the lung cancer preferably includes non-small cell lung cancer.

[0050] The application further provides a medicine for treating postoperative discomfort of lung cancer and / or reducing lung nodules, wherein a raw material for preparing the medicine comprises the traditional Chinese medicine composition.

[0051] In the application, the medicine preferably further comprises a medically acceptable auxiliary; the medically acceptable auxiliary preferably comprises sucrose and / or dextrin; and the dosage form of the medicine preferably comprises a decoction, a tablet, a capsule, a granule, an oral liquid or a dripping pill.

[0052] The application further provides a preparation method of the medicine, comprising the following steps:

[0053] The traditional Chinese medicine composition is decocted to obtain a medicinal liquid.

[0054] Preferably, the traditional Chinese medicine composition is mixed according to a proportioning, soaked in 8-10 times of water for 60-120 minutes, and then decocted for 0.5-1 hour, and filtered to obtain the medicinal liquid.

[0055] In the application, when the dosage form of the medicine is a granule, the preparation method preferably further comprises the following steps:

[0056] The medicinal liquid is concentrated and mixed with dextrin to obtain a mixture;

[0057] The mixture is mixed with an ethanol solution to obtain a soft material;

[0058] The soft material is sieved and dried to obtain the granule.

[0059] In the application, the dextrin preferably comprises malt dextrin; and the volume concentration of the ethanol solution is 90%.

[0060] The application further provides an application of the medicine or the medicine prepared by the preparation method in preparing a product for treating postoperative discomfort of lung cancer and / or reducing lung nodules.

[0061] In order to further illustrate the present application, a kind of traditional Chinese medicine composition for treating postoperative discomfort of lung cancer and / or reducing lung nodule and its application provided by the present application are described in detail below in conjunction with the accompanying drawings and examples, but they cannot be understood as limiting the scope of protection of the present application.

[0062] Example 1

[0063] The granules for postoperative lung cancer in this example are prepared from the following raw medicinal materials by mass fraction: 15 parts of floating sea stone, 9 parts of xuanfuphua, 30 parts of huangqi, 6 parts of wuweizi, 12 parts of danggui, 15 parts of baishao, 15 parts of jixueteng, 10 parts of xiaakucao, 9 parts of yimucao, 10 parts of pugongying, 30 parts of baihuasheshecao, 15 parts of jinqiao mai, 10 parts of jiangteng, and 10 parts of gancao.

[0064] The above raw medicinal materials are mixed according to the mass ratio, soaked in water for 1 hour, decocted for 1 hour, filtered, and then the filtrate is concentrated to obtain thick extract (relative density 1.30-1.35). After drying under reduced pressure, the dry extract powder is obtained by crushing. The dry extract is mixed with maltodextrin at a mass ratio of 1:1 to obtain a mixed powder. Then, the mixed powder is added with 90% ethanol-water solution by volume fraction to prepare soft material. The soft material is sieved to obtain wet granules.

[0065] Example 2

[0066] The traditional Chinese medicine decoction for postoperative lung cancer in this example is prepared from the following raw medicinal materials by mass fraction: 15 parts of floating sea stone, 9 parts of xuanfuphua, 30 parts of huangqi, 6 parts of wuweizi, 12 parts of danggui, 15 parts of baishao, 15 parts of jixueteng, 10 parts of xiaakucao, 9 parts of yimucao, 10 parts of pugongying, 30 parts of baihuasheshecao, 15 parts of jinqiao mai, 10 parts of jiangteng, and 10 parts of gancao.

[0067] First decoction: micro-pressure decoction, and maintain boiling; stop heating and collect the medicinal liquid while hot, squeeze the medicinal materials until there is no residual medicinal liquid, and store the medicinal liquid separately; second decoction: add water: measure the temperature of the medicinal materials, and add pure water not less than the measured temperature to the medicinal materials until it exceeds the upper surface of the medicinal materials; second decoction: atmospheric pressure decoction and maintain boiling, stop heating and collect the medicinal liquid while hot, squeeze the medicinal materials until there is no residual medicinal liquid, and mix the two medicinal liquids evenly; take the content of astragaloside A in huangqi and ferulic acid in danggui as the index components for quality control, perform peak matching according to UPLC-Q-TOF-MS for content detection, and the index components of each batch are stable at M±20%, and if qualified, they are packaged by dose; if unqualified, they are concentrated until the content of the medicinal preparation is qualified.

[0068] Example 3

[0069] The present embodiment is applied to a traditional Chinese medicine decoction after lung cancer surgery, and each dose of the medicine is prepared from the following raw medicinal materials: 15 parts of floating sea stone, 9 parts of xuanfuhua, 30 parts of huangqi, 6 parts of wuweizi, 12 parts of danggui, 15 parts of baishao, 15 parts of jixueteng, 10 parts of xiaakucao, 9 parts of yimucao, 10 parts of pugongying, 30 parts of baihuasheshecao, 15 parts of jinqiao mai, 10 parts of jiegeng, and 10 parts of gancao.

[0070] The medicinal materials are cleaned and mixed for soaking for 30-120 minutes, and then triple purified water is added for decoction. After boiling, the decoction is concentrated to half, filtered, concentrated to 400 ml, and then divided into two portions for packaging, so as to facilitate morning and evening taking.

[0071] Example 4

[0072] In the clinic, 10 cases of lung cancer after surgery were given one dose of the granules prepared in Example 1 of the present application per day for the treatment of postoperative discomfort.

[0073] Inclusion criteria:

[0074] ① After lobectomy, segmental resection or wedge resection, pathological examination confirmed as carcinoma in situ, microinvasive carcinoma or invasive lung cancer, and determined as 0 or I A stage lung cancer after surgery, tumor marker normal, only CT examination follow-up was needed for the patients;

[0075] ② Patients with postoperative discomfort symptoms and still existing lung nodules;

[0076] ③ Age 20-80 years old, complete medical record data;

[0077] Exclusion criteria:

[0078] ① Patients with serious primary diseases of cardiovascular, cerebrovascular, liver, kidney, blood system and the like;

[0079] ② Patients with active pulmonary tuberculosis, pneumonia and other infectious diseases;

[0080] ③ Patients with mental diseases;

[0081] ④ Pregnant and lactating women.

[0082] Implementation method:

[0083] The granules prepared in Example 1 are taken one dose per day, 10 g each time, taken in the morning and evening, and the treatment course is 2 months.

[0084] Observation index:

[0085] (1) Symptom change, according to no, mild, moderate and severe symptoms, 0, 2, 4 and 6 points are recorded, and the symptom score data of the patients before and after treatment are collected.

[0086] (2) Changes in pulmonary nodules, comparing the chest thin layer CT examination data of the patients before and after treatment, observing the size changes of the pulmonary nodules.

[0087] Primary outcome:

[0088] The results of 10 cases (marked as application examples 1-10) of early lung cancer patients before and after treatment are shown in Figure 1 The average symptom score before treatment was 7.8, and the average symptom score after treatment was 3.8. The cure rate of coughing was 55.6%, the cure rate of expectoration was 20%, the cure rate of fatigue was 42.9%, the cure rate of sweating was 66.7%, and the cure rate of constipation was 33.3%. The improvement rate of general malaise was 80%. The changes of target pulmonary nodules before and after treatment in lung cancer patients are shown in Figure 2 The shrinkage rate of the nodules was 30%.

[0089] Some specific diseases are as follows:

[0090] Application example 8, female, 70 years old, physical examination found multiple nodules in the lung, right upper lobe wedge resection in 2016, stage IA, pathology showed low differentiated adenocarcinoma, the patient still had cough, expectoration, shortness of breath, fatigue, sleep, and hard stool six months after surgery, right upper lobe 8mm nodule (non-surgical lobe), so the patient was treated, and the patient's symptoms improved significantly after being treated with the granules of the application for more than two months. The patient did not complain of cough, expectoration, shortness of breath, fatigue, sleep, and still dry stool, but the symptoms were significantly improved compared with before treatment. CT reexamination found that the pulmonary nodules were significantly reduced (see Figure 3 ), and the patient continued to take the traditional Chinese medicine composition for conditioning.

[0091] Example 5

[0092] The main effective components and target points of the traditional Chinese medicine composition provided by the application.

[0093] The "Chinese medicinal material database" module in the traditional Chinese medicine integrated pharmacology research platform TCMIP is used to search for the chemical components contained in each traditional Chinese medicine in the traditional Chinese medicine composition of the application, and only the chemical components with a "Druglikeness Grading" score of GOOD are retained, and the target points corresponding to the scores greater than 0.8 are recorded as effective target points. After screening, a total of 52 effective components with a score of GOOD are obtained, of which 4 are in Jixiehua, 1 is in Huangqi, 6 are in Danggui, 4 are in Jixueteng, 11 are in Weweizi, 9 are in Gancao, 19 are in Yimucao, Kumatakenin is common to Gancao and Huangqi, and 3-O-trans-feruloylquinic acid is common to Jixiehua and Danggui. The relevant information is shown in Table 1. A total of 148 action target points are obtained.

[0094] Table 1 Effective components of the traditional Chinese medicine composition

[0095]

[0096]

[0097] The English academic name "Post-operative lung cancer / Post-operative treatment of lung cancer / Lung cancer after surgery" after lung cancer surgery is introduced into the OMIM disease database and the GeneCards database, and the species is set as "Homo sapiens". The target points in the above databases are integrated into the postoperative disease target points of lung cancer. A total of 912 disease targets are screened from the OMIM database, and a total of 1587 disease targets are screened from the GeneCards database. By integrating the two databases, a total of 2373 postoperative disease targets of lung cancer are obtained.

[0098] The relevant target points of the active ingredients of the application and the postoperative target points of lung cancer are drawn into a Wayne diagram, so as to obtain intersection target points, i.e. target points for treating postoperative lung cancer, a total of 46, see Figure 4 , The top-ranked target points are TP53, IL-6, TNF, AKT1, and HSP90AA1. The intersection target points are uploaded to the STRING11.0 database to construct the PPI network, and then visualized using CytoScape software, see Figure 5 . The active chemical ingredients of the application and the intersection target points are uploaded into the CytoScape software to construct a drug ingredient-intersection target point diagram, see Figure 6 .

[0099] Based on the Metascape platform, the intersection target points are subjected to GO function enrichment analysis and KEGG pathway enrichment analysis. The GO function enrichment analysis includes biological processes, molecular functions and cellular components. The analysis results are sorted in descending order according to the P value, and the top 20 GO functions and KEGG pathways that meet the conditions are selected. The visualization of the screening results is realized by using the micro-Bioinformatics platform, see Figures 7-10 . The results show that the GO function enrichment analysis mechanism is in the cell response to organic cyclic compounds, response to hormones, transcriptional regulatory complex, receptor complex, nuclear receptor activity, and activated ligand transcription factor activity. The KEGG pathway enrichment analysis mechanism is in lipid and atherosclerosis, PI3K-AKT pathway, IL-17 signaling pathway, etc.

[0100] Although the above embodiments have made a detailed description of the present application, it is only a part of the embodiments of the present application, not all the embodiments, and other embodiments can be obtained according to the present embodiments without creativity, which belong to the protection scope of the present application.

Claims

1. A traditional Chinese medicine composition, characterized in that, The Chinese medicine composition is prepared from the following components in parts by mass: floating stone 15-60 parts, xuanfuping 5-10 parts, huangqi 30-50 parts, wuweizi 5-10 parts, danggui 10-20 parts, baishao 10-20 parts, jixueteng 10-20 parts, xiaakucao 10-20 parts, yizhi 9-15 parts, yimucao 20-30 parts, pugongying 10-20 parts, baihuashexiecao 20-30 parts, jinqiao 10-20 parts, jiegeng 10-20 parts, and gancao 5-10 parts.

2. The traditional Chinese medicine composition according to claim 1, characterized in that, The Chinese medicine composition is prepared from the following components in parts by mass: floating stone 15 parts, xuanfuping 9 parts, huangqi 30 parts, wuweizi 6 parts, danggui 12 parts, baishao 15 parts, jixueteng 15 parts, xiaakucao 10 parts, yizhi 9 parts, yimucao 30 parts, pugongying 10 parts, baihuashexiecao 30 parts, jinqiao 15 parts, jiegeng 10 parts, and gancao 10 parts.

3. Use of the Chinese medicine composition of claim 1 or 2 in the preparation of a medicament for treating postoperative discomfort of lung cancer and / or reducing lung nodules.

4. Use according to claim 3, characterized in that, The postoperative discomfort of lung cancer includes one or more of the following symptoms: cough, expectoration, chest pain, fatigue, sweating, and constipation.

5. A medicament for treating postoperative discomfort of lung cancer and / or reducing lung nodule, characterized by, The preparation of the medicament includes the Chinese medicine composition of claim 1 or 2.

6. The medicament according to claim 5, characterized in that, The medicament further includes pharmaceutically acceptable excipients.

7. The medicament according to claim 5, characterized in that, The dosage form of the medicament includes decoction, tablet, capsule, granule, oral liquid, or dripping pill.

8. Process for the preparation of a medicament according to any one of claims 5 to 7, characterized in that, The method includes the following steps: The Chinese medicine composition of claim 1 or 2 is decocted to obtain a medicinal liquid.

9. The production method according to claim 8, characterized by, When the dosage form of the medicament is granule, the preparation method further includes the following steps: The medicinal liquid is concentrated and mixed with dextrin to obtain a mixture; The mixture is mixed with an ethanol solution to obtain a soft material; The soft material is sieved and dried to obtain the granule.

10. Use of the medicament of any one of claims 5-7 or the medicament prepared by the preparation method of claim 8 or 9 in the preparation of a product for treating postoperative discomfort of lung cancer and / or reducing lung nodules.

Images